 Biocept Inc NASDAQ:BIOC FRA:B003 will host a webinar featuring leading neuro-oncologists to discuss the use of its proprietary cerebrospinal fluid CSF assay for diagnosing and managing tumors that have metastasized to the central nervous system CNS, including the brain or spinal column. The company said its CSF assay provides enhanced sensitivity compared with CSF cytology, the current standard-of-care, and has the added advantage of identifying actionable molecular targets for use in treatment decisions while providing quantitative information needed for assessing treatment response and monitoring disease progression. 